Ohio State Navbar


Zongdi Feng, PhD

700 Children's Drive
Columbus, OH 43205

Email: feng.581@osu.edu


Current OSU Appointment

Assistant Professor, Pediatrics


Curriculum Development

I have taught a virology course (MVIMGVBS/MG7741) for graduate students at OSU in 2015 and 2016. I gave a lecture on picornaviruses in the section of “Positive-strand RNA viruses” in both years, and co-taught a lecture on “Hepatitis B virus and hepatitis D virus” with Dr. Christopher Walker. This team teaching approach worked well. I also served as the section leader for “Positive-strand RNA viruses” in 2016.



Master/Graduate Advising

Nothing to report (I haven’t had graduate students yet).

Approach & Goals to Teaching

As a principal investigator at the Research Institute at Nationwide Children’s Hospital (TRINCH), my teaching responsibility is mainly focused on training post-docs, summer students, and research staff. My goal for post-docs is to prepare them for conducting independent research. I assign projects based on their research interests and skills, and guide their research through their projects. I urge them to read broadly, think critically, design experiments robustly, interpret results thoroughly, and draw conclusions conservatively. I also regularly ask post-docs to present their research at national conferences where they can interact with other researchers, receive feedback, and learn new knowledge. My goal for summer students is that in a 10-12 week period they will learn basic knowledge about of our lab research, complete a small research project, and make a short presentation about their work.

I also participate in class teaching a graduate virology course at OSU. This course (Molecular Virology and Pathogenesis of Viruses) is directed by Dr. Li Wu. The class is relatively small (7 students in 2015 and 12 students in 2016), and consists of lectures and student paper discussions. My goal in teaching this class is that students will understand the general principles and describe key experimental findings on given topics. As a small group, I encourage students to ask questions and make comments during the class and use this opportunity to explain and elaborate related topics in greater detail as needed.   

Evaluation of Teaching

In 2015 I gave a lecture on “Picornaviruses” and received an average score of 8.0 on a 0-10 scale from 4 (out of 7) students who responded. Overall, the evaluations were very positive, such as “it was fantastic experience to listen to all the experts from different field in one course”, and “the course is well laid-out and progresses logically for each virus module”, and “this was the most informative and useful class I have taken at OSU”. Some of the students’ suggestions include: adding “one review class before the final exam”, and “more participation from the instructors during the student seminars, so they could gain more information from the discussions”.


In 2016, in addition to the “Picornaviruses” lecture, I participated in team teaching with Dr. Christopher Walker. We had 2 students give presentations on assigned papers followed by group discussion. In the second part we provided a lecture on hepatitis B virus with Dr. Walker focusing on the pathogenesis while I focused on the molecular virology. I received an average score of 6.7 (0-10 scale). While the general feedback and comments are positive, one helpful suggestion I received was that the learning objective of my lecture on HBV were not clear. This is something that I will improve this year.

Continuing Education, Extension, and Other Courses Taught

Nothing to report.

Noteworthy Graduate Narrative

Nothing to report (I haven’t had graduate students yet).

Advising Narrative

Nothing to report.

Undergraduate, Graduate, and Professional Courses Taught

I have taught in the virology course (MVIMGVBS/MG7741) for graduate students at OSU in 2015 and 2016 and served as the section leader for “positive-strand RNA viruses” in this course in 2016.


Service Activities

Institutional committees: I have served on a number of committees at NCH, including the Finance and Sponsored Projects Advisory Committee, the Research Retreat Committee, the Seminar Committee. I have also served as a judge for the NCH Infectious Disease Consortium Research Day and for selecting abstracts for oral presentation for the 2015 NCH Research Day.


Grant reviewer and judge: I have served as a grant reviewer for the 2015 Deans’ Discovery Grants Program & Nationwide/COM Cross-Campus-Collaborative Pilot Program, the 2015 NCH Disease Consortium Intramural Funding Program (6 applications including 2 from faculty members and 4 from trainees), and the Czech Science Foundation Panel 302 (Morphological disciplines, microbiology, immunology, epidemiology and hygiene) in 2016.


Peer reviewer for manuscripts: I regularly serve as a peer reviewer for manuscripts for journals such as PLoS Pathogens, mBio, and the Journal of Virology. In the past 3 years, I have reviewed >40 manuscripts including 24 manuscripts for the Journal of Virology. I strive to provide thorough and constructive comments, with the goal of improving the quality of the manuscript to meet the standards of given journals. Even for manuscripts that are unlikely to be accepted even after revision, I still provide suggestions/comments that I hope the authors will find useful in improving their work and publish it elsewhere.


Editorial Board: I was invited by the Editor-in-Chief of the Journal of Virology last year to serve on the editorial board (2017-2019). The Journal of Virology is the most prestigious journal in the field of virology.

Student Life Activity Narrative

I actively participate in the local scientific community. For example, I gave a seminar on my research for The Ohio Virology Association (OVA), a student-organized seminar series at OSU. I also served as a faculty mentor for a high school student Hannah Lee (winner of the 2015 NCH Mechanism of Human Health and Disease Program) in support of her group project for summer students in the 2016 NCH Mechanism Program.




Academic Advising

Xin Yin, Postdoctoral Associate, 2014-present

Xinlei Li, Research Scientist, 2015-present

Sebastien Lhomme, Postdoctoral Associate, 2015-present

Zhimin Hu, Visiting Scholar (China), 2015-2016

Deepthi, Summer Undergraduate Student (Duke University), 2015

Hannah Lee, Summer High School Student (Darby High School, now at Yale University), 2016

Professional Interests Narrative

I enjoy mentoring postdocs and look forward to mentoring graduate students in the future. It’s very rewarding to witness their growth and development into productive independent researchers over time.

Partnership Narrative

  • In collaborative work with Dr. Brian Borg (University of Mississippi Medical Center) we proposed an algorithm for the diagnosis and management of pre- and post-transplantation hepatitis E (Clin Transplant, 2016).

  • In collaborative work with Dr. Takeshi Saito (University of South California) we reported the presence of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antivirals but experienced recurrent infection after liver transplantation (Gastroenterology, 2017).

  • We have ongoing collaborations with Dr. Christopher Walker (TRINCH), an expert on T cell immunity in hepatitis virus infection, to investigate the role of neutralizing antibody in the control of HEV infection during acute and chronic HEV infection in a rhesus macaque model.

  • In collaboration with Drs. Zizheng Zheng and Ningshao Xia at the Xiamen University, we are investigating the role of antibody escape in chronic HEV infection and the function of HEV free antigen in vivo.

  • We are collaborating with Dr. Susan Hafenstein (Pennsylvania State University) to investigate the structural changes in HEV virions caused by low pH using cryoEM.

  • In collaboration with Dr. Adonis Stassinopoulos at the Cerus Cooperation, a company that focuses on blood product safety, we are investigating the impact of envelopment of HEV on its inactivation by their INTERCEPT blood system that is used to sterilize blood product for use in patients.

  • We have an ongoing collaboration with Dr. Jacob Yount (OSU) to investigate the role of palmitoylation in the subcellular localization of the HEV ORF3 protein and its role in HEV release from infected cells.



I obtained a bachelor’s degree from the Wuhan University and a master’s degree from the Wuhan Institute of Virology of the Chinese Academy of Sciences. In 2002, I came to the U.S. to pursue my PhD at the University of Illinois at Chicago, working in Dr. Bin he’s lab on the mechanisms of immune evasion by the herpes simplex virus and the Ebola virus. I was the first to demonstrate that the Ebola virus protein VP35 is an interferon antagonist by blocking PKR-mediated protein translation shutoff. This paper was well recognized by the field and has been cited 139 times according to Google Scholar. In 2008, I joined the laboratory of Dr. Stanley Lemon as a postdoc to work on innate immune responses to hepatitis viruses. My most notable contribution during this period was the discovery of enveloped hepatitis A virus (eHAV), which blurs the distinction between enveloped and nonenveloped viruses. This paper has been cited 180 times since it was published in Nature in 2013.


Upon completion of my postdoctoral training in 2014, I joined the faculty of The Ohio State University/Nationwide Children’s Hospital (NCH) as an Assistant Professor of Pediatrics. My research at NCH has been focused on hepatitis E virus (HEV), an important human pathogen that causes significant liver disease worldwide but has been extremely understudied due to a lack of efficient cell culture systems. Through our effort, we have now developed a robust culture system for HEV. Using this system, we are now able to dissect the full life cycle of HEV and its host cell interactions at an unprecedented level. So far, my independent research at NCH has resulted in 7 peer-reviewed publications in high profile journals including the Journal of Virology and PLoS Pathogens, and five of them are on HEV. Results of my research efforts have been well received by colleagues. According to Google Scholar, my publications have been cited 919 times with an h-index of 15. I was invited to presented our research at universities, and national and international conferences. The reagents generated in my own laboratory (such as cell lines and plasmids) have been requested by researchers from different countries. I was invited to write reviews based on our published work and provide commentaries to controversial topics in the HEV field. In addition, my work was identified by a company resulting in a contract on a collaborative project to determine the effect of HEV envelopment on its inactivation by the company’s pathogen inactivation system.


Since I joined NCH, I have identified several collaborators in the field, and established long-term collaborations with Dr. Christopher Walker (NCH) to investigate immunity and pathogenesis of HEV infection in a monkey model, and with Dr. Zizheng Zheng (Xiamen University, China) to investigate the antibody response during HEV infection or vaccination. More details can be found in “Partnerships & Collaborations”.


I have aggressively applied for research funding and so far have submitted 8 proposals to government agencies and private foundations. In 2015, I was awarded a 3-year grant from the American Society of the Study of the Liver Diseases Foundation to study the mechanism for immune control of HEV. In 2016, I was awarded an R21 grant from NIH to study the impact of envelopment on HEV infection and immunity. I am also an active member of professional societies including the American Society for Virology and the American Society for the Study of Liver Diseases. I serve on the editorial board for the Journal of Virology (a top journal in the virology field) and have frequently served as a peer reviewer for scientific journals including PLoS Pathogens, Journal of Virology, mBio, and Journal of Hepatology.

Focus of Research

The research in my lab has focused on the role of envelopment on the hepatitis E virus (HEV) life cycle and pathogenesis. HEV infects ~20 millions of people each year causing significant morbidity and mortality but has been extremely understudied. HEV infection of immunocompromised patients often leads to persistence. Currently there is no FDA-approved diagnostic or treatment. HEV has a unique dual life style in that it is shed into the feces as naked virus but circulates as enveloped virus in the blood. The ultimate goal of our work is to develop a better understanding of HEV infection and pathogenesis for generating better strategies for prevention and treatment. During past 3 years, we have developed an efficient culture system for HEV, which had been a major obstacle in the field. Using this system, we have demonstrated that the enveloped and nonenveloped forms of HEV utilize distinct mechanisms for cell entry (Yin et al. J Virol. 2015). Based on this knowledge and using the CRISPR knockout library, we are currently working to identify host factors that are commonly or differentially required for infection by the two different forms of HEV. This study may allow us to identify the cellular receptor for HEV; the identification of which will not only facilitate our understanding of HEV entry but also provide a potential target for antiviral therapy.


A second area of our research is to understand how HEV is released from infected cells. Previous work by other groups have shown that the HEV ORF3 protein is essential for HEV envelopment and release. We have generated data suggesting an ORF3-independent mechanism for HEV release. In addition, we found that ORF3 is mainly concentrated at the apical/canalicular membrane of HEV-infected hepatocytes, suggesting ORF3 is important for HEV release into the bile. We have identified a motif in ORF3 that is required for its apical membrane localization, and are collaborating with a group in China to determine the role of this motif in HEV release into bile and feces in animal models.


Another area that we focus on is the immune evasion mechanisms of HEV and how they contribute to pathogenesis. We have also demonstrated that unlike other hepatotropic RNA viruses (e.g., hepatitis A virus and hepatitis C virus), HEV does not block IFN production. Instead, it has evolved a unique strategy to persist in the presence of the host IFN response (Yin et al. PLoS Pathogens, 2016). We found that HEV-infected cells are highly resistant to exogenous IFN treatment, and blocking endogenous IFN signaling elicited by HEV restored the sensitivity of HEV-infected cells to exogenous IFNs. These findings are likely to be relevant for HEV persistence in vivo, since increased expression of IFN-related genes is often observed in patients chronically infected with HEV. Currently we are investigating the underlying mechanism by which HEV persists in the presence of IFN signaling and whether there is difference between different HEV genotypes.


In addition, we recently discovered a novel secreted form of HEV capsid antigen that is released in high abundance from infected cells. Preliminary characterizations suggest that it behaves very similarly to the hepatitis B virus e antigen (HBeAg), which plays important roles in HBV persistence and liver injury. We are currently investigating the impact of this secreted antigen on the HEV life cycle and pathogenesis.


Since I joined NCH in 2014, I have established collaborations with several groups in the field. In collaboration with Dr. Christopher Walker (NCH), we are investigating antibody response during acute HEV infection in a macaque model. I have ongoing collaborations with Drs. Zizheng Zheng and Nishao Xia at the Xiamen University in China, who developed the first vaccine for genotype 1 HEV, to investigate the role of antibody escape in chronic HEV infection and the function of HEV free antigen in pathogenesis. In addition, my published work was identified by the Cerus Cooperation, a company that focuses on blood product safety. We are currently working with this company to determine the impact of envelopment of HEV on its inactivation by their INTERCEPT blood system.

Published Works

During my PhD and postdoctoral training, I published 15 papers in high-quality, peer reviewed journals such as Nature, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, USA, and Journal of Experimental Medicine. My most significant contributions to science include: discovery that the Ebola virus VP35 protein is an interferon antagonist that blocks cellular protein kinase R (PKR), discovery and characterization of a novel enveloped form of hepatitis A virus. Since I joined NCH in 2014, I have authored or co-authored 8 peer-reviewed papers in high-quality journals including Science, Gastroenterology, PLoS Pathogens, Journal of Virology, 1 book chapter, and 1 online publication. According to Google Scholar, my publications have been cited 919 times with an h-index of 15.




Research Funding

In addition to the start-up funds from NCH, I am the PI on a 3-year grant (the Pinnacle Research Award) from the American Society of the Study of the Liver Diseases (AASLD) Foundation. The goal of this grant is to understand the role of envelopment on HEV entry and sensing by innate immune cells. I am also the PI on an NIH R21 grant, the goal of which is to understand the impact of envelopment on HEV cell entry and antibody neutralization.


I also submitted an R01 to study the mechanism of HEV entry and spread and received a favorable score, and an R21 to investigate the function of a novel antigen of HEV that we recently discovered. This application will be reviewed in October, 2017.

Research Interest

I have a long-term interest in discovering novel virus-host interactions in the context of viral pathogenesis. My previous research as a post-doctoral fellow in Dr. Stanley Lemon’s laboratory focused on the mechanisms of innate immune activation and evasion by hepatitis A virus (HAV). My most significant contribution to the scientific community is the discovery and characterization of ‘quasi-enveloped’ HAV. Since I began my independent research in 2014 in the Research Institute at Nationwide Children’s Hospital (TRINCH), my laboratory has mainly focused on hepatitis E virus (HEV), another hepatotropic RNA virus that causes significant morbidity and mortality, but is extremely understudied. There was no efficient cell culture system to study HEV when I started my lab. In the past three years, we have developed robust culture systems for HEV that allow us to study this virus in unprecedented detail. Our research has so far led to two research papers: one on the entry mechanism of quasi-enveloped HEV particles, published in the Journal of Virology in 2016, and another on the interactions between HEV and the interferon system, which was published recently in PLoS Pathogens. In addition, we recent discovered a new HEV protein with potential immune regulatory roles. Using the efficient HEV cell culture system that we have developed, we are determining how this novel HEV protein is produced and whether it functions as an immune decoy. We have several ongoing collaborations with Dr. Christopher Walker (NCH) to investigate HEV and host interactions in a rhesus macaque model.




Creative Works

I wrote a reviewer article for Viruses to propose a model on the role of envelopment in the life cycle and pathogenesis of HEV (Viruses, 2016). I also wrote a commentary (on the con side) for the “Debate in hepatology” regarding the extrahepatic manifestations of HEV infection (Liver Int., 2016).


Quality Indicators

HEV is an important human pathogen but has been extremely understudied. Part of the reason is that there has been no efficient cell culture systems to study HEV. We are among the few labs in the world that are actively studying this virus in culture systems. We have developed efficient cell culture system for HEV and published two research papers on HEV in the Journal of Virology (impact factor: 4.66) and PLoS Pathogens (impact factor: 6.6), both rated top journals in the virology field. The PLoS Pathogens paper has been viewed 2,712 times since it was first published in May 30, 2017, and several groups have requested the cell lines and plasmids that we described in this paper for their research. 


Postdoctoral / Researcher Advising

Yin X, Li X, Ambardekar, Hu Z, Lhomme S, Feng Z*. Hepatitis E Virus Persists in The Presence of A Type III Interferon Response. PLoS Pathogens. 2017 May 30; 13(5):e1006417. Doi: 10.1371/journal.ppat.1006417. PMID: 28558073.


Yin X, Ambardekar C, Lu Y, and Feng Z*. Distinct Entry Mechanisms by Non-Enveloped and Quasi-Enveloped Hepatitis E Virus. J. Virol. 2016 Feb 10. pii: JVI.02804-15. PMID: 26855708.


Xin Y, Li X, Feng Z*. Role of Envelopment in HEV Life Cycle. Viruses. 2016. Aug 18:8(8). pii: E229. doi:10.3390/v8080229. PMID:27548201

Chapters in Books

Feng Z, Chen X. "Viral Infection and Cellular Apoptosis." In General Virology. Edited by Xie T, Hu Z. 177-195. Wuhan, CN|CHN: Science Publishing House, January 2002.

Feng Z, Lemon SM. "Pathogenesis of Hepatitis A Virus Infection." In The Picornaviruses: Molecular Biology, Evolution and Pathogenesis. Edited by Domingo E, Ehenfeld E, Roos R. 383-396. Washington, DC, US|USA: American Society of Microbiology Press, January 2010.



1999 B.S., Wuhan University

2002 M.S., Chinese Academy of Sciences


Editorial Activities

2014 - present Cellular Immunology
2014 - present Journal of Clinical Microbiology
2014 - present Journal of Virology


2001 DIAO Graduate Fellowship. Chinese Academy of Sciences.
2009 Travel Award "Pattern Receptors and Innate Immune Signaling Pathways in Liver Diseases". The Henry M. and Lillian Stratton Basic Research Single Topic Conference.
2012 Travel Award. 31st American Society of Virology Annual Meeting.
2013 3rd place, 3rd Annual Oliver Smithies Nobel Symposium Postdoctoral Researcher Poster Forum. University of North Carolina at Chapel Hill.
2013 Best Poster Award, Center of Gastrointestinal Biology and Disease Annual Retreat. University of North Carolina at Chapel Hill.
2014 Lineberger Comprehensive Cancer Center Joseph S. Pagano Award. University of North Carolina.
2015 - present Pinnacle Research Award on Liver Diseases.. NA.

Journal Articles

Feng Z, Chen X, Vlak JM, Hu Z. "Sequence Analysis of the XbaI-I Region in Genome of the Single Nucleocapsid Nucleopolyhedrovirus of Helicoverpa armigera." Virologica Sinaca. Vol. 17, no. 2. (January 2002.): 125-131.

Lu Y, Feng Z, Wu D, Yuan L, Hu Z. "Study of Foreign Baculoviral ctl Gene by Overexpression Using AcMNPV Bacmid System in vivo." Virologica Sinaca. Vol. 19, no. 3. (January 2004.): 276-280.

Cheng G, Feng Z and He B. "Herpes Simplex Virus 1 Activates PERK and Blocks ER Stress Induced Translation Inhibition Through gamma(1)34.5 Protein.." J Virol. Vol. 79, no. 3. (February 2005.): 1379-88.

He F, Wang X, He B, Feng Z, Lu, Zhang Y, Zhao S, Lin R, Hui Y, Bao Y, Zhang Z and Wen H. "Human Herpesvirus 8: Seroprevalence and Correlates in Tumor Patients from Xinjiang of China.." J Med Virol. Vol. 79, no. 2. (February 2007.): 161-6.

Feng,Zongdi; Cerveny,Melissa; Yan,Zhipeng; He,Bin. "The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR." JOURNAL OF VIROLOGY. Vol. 81, no. 1. (January 2007.): 182-192.

Jin,Huali; Ma,Yijie; Prabhakar,Bellur,S; Feng,Zongdi; Valyi-Nagy,Tibor; Yan,Zhipeng; Verpooten,Dustin; Zhang,Cuizhu; Cao,Youjia; He,Bin. "The gamma(1)34.5 Protein of Herpes Simplex Virus 1 Is Required To Interfere with Dendritic Cell Maturation during Productive Infection." JOURNAL OF VIROLOGY. Vol. 83, no. 10. (May 2009.): 4984-4994.

Verpooten,Dustin; Feng,Zongdi; Valyi-Nagy,Tibor; Ma,Yijie; Jin,Huali; Yan,Zhipeng; Zhang,Cuizhu; Cao,Youjia; He,Bin. "Dephosphorylation of eIF2 alpha Mediated by the gamma(1)34.5 Protein of Herpes Simplex Virus 1 Facilitates Viral Neuroinvasion." JOURNAL OF VIROLOGY. Vol. 83, no. 23. (December 2009.): 12626-12630.

Stavrou,Spyridon; Feng,Zongdi; Lemon,Stanley,M; Roos,Raymond,P. "Different Strains of Theiler's Murine Encephalomyelitis Virus Antagonize Different Sites in the Type I Interferon Pathway." JOURNAL OF VIROLOGY. Vol. 84, no. 18. (September 2010.): 9181-9189.

Jin,Huali; Yan,Zhipeng; Prabhakar,Bellur,S; Feng,Zongdi; Ma,Yijie; Verpooten,Dustin; Ganesh,Balaji; He,Bin. "The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide." JOURNAL OF GENERAL VIROLOGY. Vol. 91, (February 2010.): 352-361.

Qu,Lin; Feng,Zongdi; Yamane,Daisuke; Liang,Yuqiong; Lanford,Robert,E; Li,Kui; Lemon,Stanley,M. "Disruption of TLR3 Signaling Due to Cleavage of TRIF by the Hepatitis A Virus Protease-Polymerase Processing Intermediate, 3CD." PLOS PATHOGENS. Vol. 7, no. 9. (September 2011.): e1002169-.

Lanford,Robert,E; Feng,Zongdi; Chavez,Deborah; Guerra,Bernadette; Brasky,Kathleen,M; Zhou,Yan; Yamane,Daisuke; Perelson,Alan,S; Walker,Christopher,M; Lemon,Stanley,M. "Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 108, no. 27. (July 2011.): 11223-11228.

Zhou,Yan; Callendret,Benoit; Xu,Dan; Brasky,Kathleen,M; Feng,Zongdi; Hensley,Lucinda,L; Guedj,Jeremie; Perelson,Alan,S; Lemon,Stanley,M; Lanford,Robert,E; Walker,Christopher,M. "Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection." JOURNAL OF EXPERIMENTAL MEDICINE. Vol. 209, no. 8. (July 2012.): 1481-1492.

Feng,Zongdi; Hensley,Lucinda; McKnight,Kevin,L; Hu,Fengyu; Madden,Victoria; Ping,Lifang; Jeong,Sook-Hyang; Walker,Christopher; Lanford,Robert,E; Lemon,Stanley,M. "A pathogenic picornavirus acquires an envelope by hijacking cellular membranes." NATURE. Vol. 496, no. 7445. (April 2013.): 367-71.

Feng,Zongdi; Lemon,Stanley,M. "Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis." TRENDS IN MICROBIOLOGY. Vol. 22, no. 2. (February 2014.): 59-64.

McGivern,David,R; Masaki,Takahiro; Williford,Sara; Ingravallo,Paul; Feng,Zongdi; Lahser,Frederick; Asante-Appiah,Ernest; Neddermann,Petra; De Francesco,Raffaele; Howe,Anita,Y; Lemon,Stanley,M. "Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors." GASTROENTEROLOGY. Vol. 147, no. 2. (August 2014.): 453-62.

Feng Z, Hirai-Yuki A, McKnight KL and Lemon SM. "Naked Viruses that Aren’t Always Naked: Quasi-enveloped Agents of Acute Hepatitis." Ann. Rev. Virol.. Vol. 1, (November 2014.): 539-560.

Yin,Xin; Feng,Zongdi. "Dissecting cellular entry mechanisms by enveloped and nonenveloped hepatitis E virus." HEPATOLOGY. Vol. 62, (October 2015.): 1039A-1039A.

Walker,Christopher,M; Feng,Zongdi; Lemon,Stanley,M. "Reassessing immune control of hepatitis A virus." CURRENT OPINION IN VIROLOGY. Vol. 11, (April 2015.): 7-13.

Feng,Zongdi; Li,You; McKnight,Kevin,L; Hensley,Lucinda; Lanford,Robert,E; Walker,Christopher,M; Lemon,Stanley,M. "Human pDCs preferentially sense enveloped hepatitis A virions." JOURNAL OF CLINICAL INVESTIGATION. Vol. 125, no. 1. (January 2015.): 169-176.

Yin X, Ambardekar C, Lu Y, Feng Z. "J Virol." Distinct Entry Mechanisms for Nonenveloped and Quasi-Enveloped Hepatitis E Viruses.. Vol. 90, no. 8. (March 2016.): 4232-42.

Borg BB, Feng Z, Earl TM, Anderson CD. "Clin Transplant." Hepatitis E in post-liver transplantation: is it time to routinely consider it?. Vol. 30, no. 9. (September 2016.): 975-9.

Yin X, Li X, Feng Z. "Viruses." Role of Envelopment in the HEV Life Cycle. Vol. 8, no. 8. (August 2016.): E229-.

Feng Z. "Live Int.." Causation by HEV of extrahepatic manifestations remains unproven.. Vol. 36, no. 4. (April 2016.): 477-9.

Feng Z*, Li Y, Hensley L, Lanford RE, Walker CM, Lemon SM*.. "Preferential Sensing of Enveloped Hepatitis A Virions by Human pDCs.." J. Clin. Invest.. -.


Reference Works

January 2011 Lanford RE, Feng Z, Chavez D, Guerra B, Brasky KM, Zhou Z, Yamane D, Walker CM, Lemon SM.."18th Int'l Symposium on Hepatitis C Virus and Related Viruses." Seattle.
January 2012 Feng Z, Lemon SM.."European Study Group on the Molecular Biology of Picornaviruses (Europic)." Sanit Raphael.
December 2013 Feng Z, McKnight KL, Hirai-Yuki A, Hu F, Lemon SM.."HEP DART 2013" Big Island.
January 2014 Lovell W, Masaki T, Feng Z, Hamlett C, Saalau-Bethell S, Graham B, McGivern D.."21st Int'l Symposium on Hepatitis C and Related Viruses" Banff.


"12. Interference of Host Interferon Responses By Ebola Virus VP35 Protein." Presented at Chicago Area Virology Association Symposium (CAVA), Chicago. (January 2008)

"9. Modulation of Host Innate Response By The Ebolavirus VP35 Protein." Presented at University of Texas Medical Branch, Galveston. (January 2008)

"8. Modulation of Host Innate Response By The Ebolavirus VP35 Protein." Presented at University of Miami, Miami. (January 2008)

"9. Modulation of Host Innate Response By The Ebolavirus VP35 Protein." Presented at Loyola University, Chicago. (January 2008)

"9. Modulation of Host Innate Response By The Ebolavirus VP35 Protein." Presented at National Institute of Environmental Health Sciences, Durham. (January 2008)

"An NALP3 Inflammasome Response Induced by Hepatitis A Virus." Presented at AASLD single topic meeting, Atlanta. (January 2009)

"Disruption of TLR-3 Response by Hepatitis A Virus." Presented at AASLD Single Topic Conference, Atlanta. (January 2009)

"L Protein of Theiler’s Virus." Presented at 16th Meeting of the European Study Group on the Molecular Biology of Picornaviruses (EUROPIC), St. Andrews, GB|GBR. (January 2010)

"Inhibition of TLR3 Antiviral Signaling by the Hepatitis A Virus 3CD Protease-polymerase Precursor." Presented at 29th American Society of Virology Annual Meeting, Bozeman. (January 2010)

"11. Exosomes Mediated Activation of Plasmacytoid Dendritic Cells." Presented at Virology in Progress, Chapel Hill. (January 2011)

"Discovery of An Enveloped Picornavirus." Presented at Flavigroup Meeting, Durham. (January 2012)

"Plasmacytoid Dendritic Cell Activation by Exosomal Transfer of Viral RNA." Presented at Keystone Symposium, Keystone. (January 2012)

"Activation of Plasmacytoid Dendritic Cells by Exosome-like Nanovesicles Secreted From Picornavirus Infected Cells." Presented at 31st American Society of Virology Annual Meeting, Madison. (January 2012)

"Discovery of A Novel Host-Enveloped Hepatovirus." Presented at 31st American Society of Virology Annual Meeting, Madison. (January 2012)

"Membrane Hijacking and the Pathogenesis of Viral Hepatitis." Presented at Pennsylvania State University, Hershey. (December 2013)

"Mechanism of Action of An Allosteric NS3 Inhibitor." Presented at HEP DART, Big Island. (December 2013)

"Contrasting Mechanisms of Entry and Antibody-mediated Neutralization of Enveloped and Nonenveloped Hepatitis A Virus." Presented at Keystone Symposium, Boston. (January 2013)

"Membrane Hijacking: Biogenesis of Enveloped Hepatoviruses and their Role in Pathogenesis of Hepatitis A." Presented at 3rd Annual Oliver Smithies Nobel Symposium Postdoctoral Researcher Poster Forum, Chapel Hill. (January 2013)

"A Pathogenic Picornavirus Acquires an Envelope by Hijacking Cellular Membrane." Presented at 39th Lineberger Cancer Center Postdoc-faculty Research Day, Chapel Hill. (January 2014)

"5. Membrane Hijacking and the Pathogenesis of Viral Hepatitis." Presented at Child Health Research Center Seminar Series, Columbus. (January 2014)

"Quasi-enveloped Viruses: New Questions for the Virologists and the Immunologists?." Presented at Ohio Virology Association, Columbus. (November 2014)

"Immune Evasion by Hepatitis A Virus." Presented at RNA Virus Seminar, Columbus. (January 2014)

"Catch Me If You Can: Intracellular Neutralization of Enveloped Hepatitis Viruses." Presented at 1st Symposium on Molecular Aspects in Virology, Mexico City. (October 2014)